TLM-001 (Therillume)

TLM-001 is an investigational neuro-oncology therapeutic candidate from Therillume for **glioblastoma multiforme**. Publicly available company pipeline materials identify it as a clinical-stage program in GBM, but do not disclose a proprietary non-code name, molecular target, active ingredient composition, route, dosage form, or detailed mechanism. Based on the available description, it is presented as a **gene-editing-based therapeutic program** developed using Therillume's proprietary gene-editing platform and translational disease-modeling approach in GBM. Because key pharmacologic details remain undisclosed in the accessible sources, TLM-001 is best characterized as an experimental antineoplastic candidate for GBM with limited public annotation beyond sponsor, indication, and development stage.